Results 1 to 10 of about 28,272 (264)

Proprotein Convertase Subtilisin/Kexin Type 9 and Inflammation: An Updated Review [PDF]

Frontiers in Cardiovascular Medicine, 2022
The function of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), a novel plasma protein, has mainly been involved in cholesterol metabolism in the liver, while, more interestingly, recent data have shown that PCSK9 also took part in the modulation ...
Na-Qiong Wu, Hui-Wei Shi, Jian-Jun Li
doaj   +3 more sources

Natural phytochemicals as small-molecule proprotein convertase subtilisin/kexin type 9 inhibitors

Tzu Chi Medical Journal
A decrease in the levels of low-density lipoprotein receptors (LDLRs) leads to the accumulation of LDL cholesterol (LDL-C) in the bloodstream, resulting in hypercholesterolemia and atherosclerotic cardiovascular diseases.
Je-Wen Liou, Pei-Yi Chen, Wan-Yun Gao, Jui-Hung Yen   +3 more
doaj   +2 more sources

Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Lipoprotein(a)

JACC: Advances
Background: Lipoprotein(a) [Lp(a)] has been independently associated with increased cardiovascular risk. Objectives: The authors examined the effect of monoclonal antibody proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) on plasma Lp(a)
Frederick Berro Rivera, MD, Sung Whoy Cha, MD, Cruz Linnaeus Louisse, MD, Genquen Philip Carado, MD, John Vincent Magalong, MD, Vincent Anthony Tang, MD, Mary Grace Enriquez, MD, Martha Gulati, MD, MS, Byambaa Enkhmaa, MD, PhD, Neha Pagidipati, MD, MPH, Nishant P. Shah, MD   +10 more
doaj   +2 more sources

ASSOCIATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 WITH HYPERTENSION AND SMOKING

Инновационная медицина Кубани, 2019
Objectives. To estimate the relationship of proprotein convertase subtilisin/kexin type 9 (PCSK9) level with blood pressure (BP) and smoking in a population of young males in Novosibirsk.Material and methods.
K. S. Benimetskaya, M. P. Yachmeneva, S. V. Astrakov, L. V. Shcherbakova, D. V. Denisova, Yu. I. Ragino, M. I. Voevoda   +6 more
doaj   +3 more sources

Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside [PDF]

Signal Transduction and Targeted Therapy
Proprotein convertase subtilisin/kexin type 9 (PCSK9) has evolved as a pivotal enzyme in lipid metabolism and a revolutionary therapeutic target for hypercholesterolemia and its related cardiovascular diseases (CVD).
Xuhui Bao, Yongjun Liang, Hanman Chang, Tianji Cai, Baijie Feng, Konstantin Gordon, Yuekun Zhu, Hailian Shi, Yundong He, Liyi Xie   +9 more
doaj   +2 more sources

Blockade of colon cancer metastasis via single and double silencing of PCSK7/PCSK9: enhanced T cells cytotoxicity in mouse and human [PDF]

Journal for ImmunoTherapy of Cancer
Background Immunotherapy approaches based on T cells provided breakthroughs in cancer treatment but could cause many immune-related adverse events, and their efficacy is limited for many cancers with an acquired dysfunction/exhaustion of T cells.
Delia Susan-Resiga, Nabil G Seidah, Nathalie Labrecque, Jean-Sebastien Delisle, Leila Jafarzadeh, Chloé Porcheron, Mailys Le Devehat, Anna Roubtsova, Hadi Bayat, Alexandra Evagelidis, Vatsal Sachan, Alexie Fonta Holder, Rachid Essalmani, Gabrielle Boudreau, Annik Prat, Rebecca Cusseddu, Jean-François Côté, Abdel-Majid Khatib   +17 more
doaj   +2 more sources

A molecular modeling approach for structure-based virtual screening and identification of novel anti-hypercholesterolemic agents from Grape

Informatics in Medicine Unlocked, 2022
Hypercholesterolemia is a potential cardiovascular hazard that requires immediate therapeutic intervention. Research has shown that 3-Hydroxy-3-methylglutaryl- CoA reductase (HMG CoA reductase) and Proprotein convertase subtilisin/kexin type 9 (PCSK9 ...
Precious A. Akinnusi, Samuel O. Olubode, Adebowale A. Alade, Samad A. Ahmed, Susan F. Ayekolu, Taiwo M. Ogunlade, Damilola J. Gbore, Olayemi D. Rotimi, Abigail O. Ayodele   +8 more
doaj   +1 more source

Injection of an improperly stored proprotein convertase subtilisin/kexin type 9 monoclonal antibody in a patient with secondary dyslipidemia from nephrotic syndrome: a case report

Journal of Medical Case Reports, 2023
Background Elevated plasma cholesterol and/or plasma triglyceride levels in nephrotic syndrome patients are the result of impaired lipoprotein clearance and a compensatory increase in hepatic lipoprotein synthesis. Plasma proprotein convertase subtilisin/
Tanawan Kongmalai, Nalinee Chuanchaiyakul, Yuttana Srinoulprasert, Nuntakorn Thongtang   +3 more
doaj   +1 more source

Serum Levels of PCSK9 Are Associated with Coronary Angiographic Severity in Patients with Acute Coronary Syndrome [PDF]

Diabetes & Metabolism Journal, 2018
BackgroundProprotein convertase subtilisin/kexin type 9 (PCSK9) is a circulating protein that promotes degradation of the low density lipoprotein receptor.
Kwi-Hyun Bae, Sung Woo Kim, Yeon-Kyung Choi, Jung Beom Seo, Namkyun Kim, Chang-Yeon Kim, Won Kee Lee, Sungwoo Lee, Jung Guk Kim, In-Kyu Lee, Jang Hoon Lee, Keun-Gyu Park   +11 more
doaj   +1 more source

Proprotein Convertase Subtilisin/Kexin 9 as a Modifier of Lipid Metabolism in Atherosclerosis

Biomedicines, 2023
Despite being the most common treatment strategy in the management of atherosclerosis and subsequent cardiovascular disease, classical statin therapy has certain disadvantages, including numerous side effects.
Anastasia V. Poznyak, Vasily N. Sukhorukov, Ilya I. Eremin, Irina I. Nadelyaeva, Nikita A. Gutyrchik, Alexander N. Orekhov   +5 more
doaj   +1 more source